Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by HonestAbeon Oct 26, 2012 2:53am
223 Views
Post# 20526198

RE: RE: RE: RE: Eye on the prize...

RE: RE: RE: RE: Eye on the prize...

"You're right, stripping is high at 10:1 but where you get it wrong is about the pre-strip included - it is lower, not higher.  ARZ doesn't plow in $9 million with another $11 million coming without understand the metallurgy of the deposit."

 

Pre-strip is the removal of overburden/waste rock before mining even commences, so if you do NOT include pre-stripping and just mine it from the beginning then the overall strip ratio should be higher since there is more waste rock to remove.  If you pre-strip (included in the analysis of the Northern report) then that should lower the strip ratio for the rest of the deposit.  I think you misinterpret what I was trying to say (i.e. that without doing the pre-strip it would have been a higher mind boggling 15:1 or 20+:1 ratio) but yes, including pre-strip lowers strip ratio for the remainder of the deposit.

 

But the rest of the stuff such as metallurgy, ore characteristics, grade, mining suitability, infrastructure, political climate, etc appear to be in order.  But if it was such an easy double or triple from this price then why have not all of the insiders been buying this up hand over fist especially this month?  I only see a token purchase from one insider this past summer.  I think the risk at these levels is very low but the market is not as transparent or easy as some might think and it is not always about manipulation as some might be inclined to think.  Or maybe management plays the sick juniors game where they encourage a low sp so they get the best chance to award themselves with risk free lowest price possible options which are guaranteed to make money in the future.

<< Previous
Bullboard Posts
Next >>